Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Scientists probe why obese people may handle thirst differently

NCT ID NCT01224704

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 17, 2026 · Updated 6 times

Summary

This completed study looked at how lean and obese individuals respond to thirst and water deprivation. Researchers gave 75 healthy men a high-salt infusion and a 24-hour water fast, measuring their thirst, hormone levels, and water intake. The goal was to understand if body fat affects water balance, not to test a treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

75 people

The number who actually took part.

Started

Oct 2010

Finished

Mar 2019

Lead sponsor

A government research agency

The lead sponsor is the US National Institutes of Health.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 50 years

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* INCLUSION CRITERIA: * Male. * Age 18-50 yrs to minimize hormonal influences on thirst perception in aging men. * BMI\<25 kg/m\^2 for the lean group and BMI \>=35 kg/m\^2 for obese group (but weigh less than 350 pounds to accommodate the DXA scanner) for the obese group. * Healthy, as determined by medical history and physical examination, without the exclusions listed below: EXCLUSION CRITERIA: History or Clinical Manifestation of: * Currently smoking * Any medications * Weight \<50kg (as the blood withdrawal limit would be exceeded) * Hemoglobin concentration \< 12mg/dl on screening labs * Type 1 or type 2 diabetes (according to World Health Organization diagnostic criteria (59)) * Endocrine disorders (Cushing's disease, pituitary diseases, hypo- or hyperthyroidism, diabetes insipidus, SIADH) * Hypertension as diagnosed and treated by an outside physician or by sitting blood pressure measurement, using an appropriate cuff, \>140/90 mmHg on two or more occasions * Fasting triglyceride concentrations \>= 500 mg/dl * Cardiovascular disease, including coronary heart disease, heart failure, arrhythmias and peripheral arterial disease * Liver disease, including cirrhosis, active hepatitis B or C and AST or ALT \>= 3x normal * Renal disease, as defined by serum creatinine concentrations \>= 1.5 mg/dl and / or proteinuria \>300 mg/day (200 (micro)g/min) * Central nervous system disease, including previous history of cerebrovascular accidents, dementia, and neurodegenerative disorders * Cancer requiring treatment in the past five years, except for non-melanoma skin cancers or cancers that have been clearly cured or, in the opinion of the investigator, carry an excellent prognosis * Infectious diseases such as active tuberculosis, HIV (by self report), chronic coccidioidomycoses or other chronic infections * Alcohol and/or current use of drugs (more than 2 drinks per day and regular use of drugs such as amphetamines, cocaine, heroin, or marijuana) * Psychiatric conditions or behaviors that would be incompatible with safe and successful participation in this study, including claustrophobia and eating disorders such as anorexia or bulimia nervosa All subjects will be fully informed of the aim, nature, and risks of the study prior to giving written informed consent. Subjects will also be specifically advised that the results of testing for drug usage will be filed in the medical record and would, therefore, be available as part of this record.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • NIDDK, Phoenix

    Phoenix, Arizona, 85014, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.